Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin (human))
(Synonyms: 肾上腺髓质素(22-52)(人体),22-52-Adrenomedullin (human)) 目录号 : GC32615
Adrenomedullin (AM) (22-52), human是一种NH2末端截断形式的Adrenomedullin (AM)，不具有六元环结构，也不保有降血压和血管舒张活性。
Cas No.:159899-65-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Adrenomedullin (AM) (22-52), human, is a NH2-terminal truncated forms of Adrenomedullin, which don’t possess the six-membered ring structure or retain the hypotensive and vasodilator activity[1, 2]. Adrenomedullin (AM) (22-52), human can be used as an antagonist of Adrenomedullin receptors[3]. Adrenomedullin (AM) (22-52), human antagonizes vasodilator responses to calcitonin gene-related peptide[4].
Adrenomedullin (AM) (22-52), human (10-7M; 60min) inhibited AM (10-7M; 30min) induced cAMP production in BACs[5]. Adrenomedullin (AM) (22-52), human (10-7M; 3 or 24h) abrogated the effect that Adrenomedullin (10-7M; 3 or 24h) evoked a small rise in adrenocorticotropic hormone (ACTH (10-8M; 3 or 24h)) stimulated corticosterone production in rat adrenocortical cells[6].
Adrenomedullin (AM) (22-52), human (250μg/rat/day; i.p. ; 2 weeks) reduced urinary protein excretion in the diabetic rats by some 40%[7]. Adrenomedullin (AM) (22-52), human (50μg/tumor; intratumoral injection; once a day for 10 days) significantly reduced the in vivo growth of the pancreatic cancer cell line, which were inoculated subcutaneously into the right flanks of severe combined immune deficiency (SCID) mice[8].
References:
[1] EGUCHI S, HIRATA Y, IWASAKI H, et al. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells [J]. Endocrinology, 1994, 135(6): 2454-8.
[2] NOSSAMAN B D, FENG C J, KAYE A D, et al. Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats [J]. Am J Physiol, 1996, 270(5 Pt 1): L782-9.
[3] AKASHI E, NAGATA S, YAMASAKI M, et al. Activation of Calcitonin Gene-Related Peptide and Adrenomedullin Receptors by PEGylated Adrenomedullin [J]. Biol Pharm Bull, 2020, 43(11): 1799-803.
[4] CHAMPION H C, SANTIAGO J A, MURPHY W A, et al. Adrenomedullin-(22-52) antagonizes vasodilator responses to CGRP but not adrenomedullin in the cat [J]. Am J Physiol, 1997, 272(1 Pt 2): R234-42.
[5] VELARD F, CHATRON-COLLIET A, COME D, et al. Adrenomedullin and truncated peptide adrenomedullin(22-52) affect chondrocyte response to apoptotis in vitro: downregulation of FAS protects chondrocyte from cell death [J]. Sci Rep, 2020, 10(1): 16740.
[6] ZIOLKOWSKA A, BUDZYNSKA K, TREJTER M, et al. Effects of adrenomedullin and its fragment 22-52 on basal and ACTH-stimulated secretion of cultured rat adrenocortical cells [J]. Int J Mol Med, 2003, 11(5): 613-5.
[7] EL ETER E A, AL-MASRI A A. Adrenomedullin mediates early phase angiogenesis induced diabetic nephropathy in STZ diabetic rats [J]. Eur Rev Med Pharmacol Sci, 2014, 18(22): 3534-43.
[8] ISHIKAWA T, CHEN J, WANG J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis [J]. Oncogene, 2003, 22(8): 1238-42.
Adrenomedullin (AM) (22-52), human是一种NH2末端截断形式的Adrenomedullin (AM)，不具有六元环结构，也不保有降血压和血管舒张活性[1,2]。Adrenomedullin (AM) (22-52), human可作为Adrenomedullin (AM) 受体的拮抗剂[3]。Adrenomedullin (AM) (22-52), human拮抗降钙素基因相关肽的血管舒张反应[4]。
Adrenomedullin (AM) (22-52), human（10-7M; 60min）可在关节软骨细胞中抑制Adrenomedullin (AM)（10-7M; 30min)诱导产生的cAMP[5]。Adrenomedullin (AM) (22-52), human （10-7M; 3 or 24h）消除大鼠肾上腺细胞内Adrenomedullin (AM)（10-7M; 3 or 24h）诱导ACTH（Adrenocorticotropic Hormone，促肾上腺皮质激素；10-8M; 3 or 24h）小幅升高刺激的皮质酮生成[6]。
使用Adrenomedullin (AM) (22-52), human（1μg/kg/day; i.p. ; 3 times a week for 8 weeks）处理糖尿病模型大鼠，Adrenomedullin (AM) (22-52), human下调糖尿病大鼠约40%的尿蛋白排泄量[7]。使用Adrenomedullin (AM) (22-52), human（25μg/kg; i.p. ; 4 day）处理右侧皮下接种的胰腺癌细胞系的SCID（severe combined immune deficiency，严重联合免疫缺陷）小鼠，Adrenomedullin (AM) (22-52), human显著抑制了肿瘤在SCID小鼠的体内生长[8]。
| Cell experiment [1]: | |
Cell lines | Bovine articular chondrocytes (BACs) |
Preparation Method | BACs were isolated from the carpal-metacarpal joint of daily slaughtered cows at the SOVIAM slaughter house. Briefly, small pieces of cartilage were harvested from joints, rinsed 3 times before being minced. Small pieces (< 2mm) were rinsed again before enzymatic digestion overnight in bacterial collagenase II at 37℃. Cells were passed through a nylon cell strainer (100μm porosity) to avoid collection of non-digested cartilage before being rinsed, counted and seeded at high density in 15ml DMEM supplemented with 10% FCS, 2mM L-glutamine, 1% antibiotics and fungizone. Cells were cultured in a dedicated incubator at 37℃ in humidified atmosphere containing 5% CO2 and 3% O2 (hypoxic condition) or atmospheric O2 content (normoxic basal condition). Medium was changed twice a week for 2 weeks to obtain confluent cell culture. Cells were then starved overnight, detached by using trypsin/EDTA, rinsed twice, then counted and plated in starvation medium before treatment. Cells were cultured directly on plastic except for TUNEL and immunostaining experiments, for which they were cultured on glass coverslips. For TUNEL and caspase activity measurements, cells were treated for 24h with 20ng/mL Fas-L. In all cases, cells were pretreated for 30min with Adrenomedullin (AM) (22-52) at 10–7M. |
Reaction Conditions | 10-7M; 30min |
Applications | Adrenomedullin (AM) (22-52), human showed significantly reduced cell death in articular chondrocytes. |
| Animal experiment [2]: | |
Animal models | Severe combined immune deficiency mice |
Preparation Method | PCI-43 cells (5×106) were inoculated subcutaneously into the right flanks of SCID mice. Tumor formation was observed every 3 days up to 3 weeks after inoculation.Tumors were treated daily with intratumoral injection of AM(1-25) or Adrenomedullin (AM) (22-52) from day 8 to day 17 after the inoculation at 50mg/tumor. |
Dosage form | 50μg/tumor; intratumoral injection; once a day for 10 days |
Applications | Adrenomedullin (AM) (22-52), human significantly reduced the in vivo growth of the pancreatic cancer cell line. |
References: | |
| Cas No. | 159899-65-7 | SDF | |
| 别名 | 肾上腺髓质素(22-52)(人体),22-52-Adrenomedullin (human) | ||
| Canonical SMILES | Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| 分子式 | C159H252N46O48 | 分子量 | 3576.04 |
| 溶解度 | DMSO : 100 mg/mL (27.96 mM; Need ultrasonic); H2O : 50 mg/mL (13.98 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2796 mL | 1.3982 mL | 2.7964 mL |
| 5 mM | 0.0559 mL | 0.2796 mL | 0.5593 mL |
| 10 mM | 0.028 mL | 0.1398 mL | 0.2796 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet